Article
D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells.
Haematologica - 1 Aug 2024
Hammon Kathrin, Renner Kathrin, Althammer Michael, Voll Florian, Babl Nathalie, Decking Sonja-Maria, Siska Peter J, Matos Carina, Conejo Zugey Elizabeth Cárdenas, Mendes Karina, Einwag Friederike, Siegmund Heiko, Iberl Sabine, Berger Raffaela S, Dettmer Katja, Schoenmehl Rebecca, Brochhausen Christoph, Herr Wolfgang, Oefner Peter J, Rehli Michael, Thomas Simone, Kreutz Marina
Abstract excerpt
D-2-hydroxyglutarate (D-2-HG) accumulates in patients with acute myeloid leukemia (AML) with mutated isocitrate dehydrogenase (IDH) and in other malignancies. D-2-HG suppresses antitumor T-cell immunity but little is known about potential effects on non-malignant myeloid cells. Here we show that D-2-HG impairs human but not murine dendritic cell differentiation, resulting in a tolerogenic phenotype with low major...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
